"annot","exactText","modality","statementType","drug1Lab","drug1Type","drug1Role","drug2Lab","drug2Type","drug2Role"
"urn:domeoclient:uuid:fa122be9-e083-454c-be3b-c348afec3b40","Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. ","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:f65cdfdc-3d09-4770-ab6c-86293a88ff8b","7.2 Effect of CYP2D6 Inhibitors on Atomoxetine In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). ","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:f265d0b0-c4ab-420f-aa91-7719498eeee1","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","azithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:f0a0107f-6ae2-4a9e-86f6-8f4180ebccfe","7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. ","ncit:positive","ncit:Qualitative","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:ef974812-bab1-4561-9731-7d4ce385cde0","Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).","ncit:positive","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:ee3e9301-0275-440b-b3a1-274d6408b2b2","Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).","ncit:positive","ncit:Qualitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:e933f2df-3e20-47f8-aea9-7ce2d2153c4e","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","pravastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:e926fa75-b7de-4d6e-844f-e3a3322c355e","In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). ","ncit:positive","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:e3ba7d4a-c6af-4ade-adff-edb3c832c673","Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. ","ncit:positive","ncit:Qualitative","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:e28e7a0b-bd1e-4fd0-9854-23786248be18","7.8 Antineoplastic Agents Verapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ","ncit:positive","ncit:Qualitative","paclitaxel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:e0172491-3cfc-4bff-ad5e-35ccc1fe20c4","In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). ","ncit:positive","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","desmethyldiazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:d8b1dde4-bb9e-423a-8fb0-1979b1e38cbf","Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.","ncit:positive","ncit:quantitative","propoxyphene","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:d24d4059-361f-46a5-9e76-f0bd18af1cb8","These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  ","ncit:positive","ncit:Qualitative","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:cf2941e0-bf6d-4d70-bf6e-1fe5565518f0","Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. ","ncit:negative","ncit:quantitative","Methotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","naproxen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:ceed343b-2c34-466f-99c6-e735ef447e30","Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. ","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:cb8009db-5bb5-40d9-bfbf-ee2f42c40079","Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects. ","ncit:positive","ncit:quantitative","sirolimus","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:c50024d9-f0b8-4c4b-b448-e1a502b6617c","Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).","ncit:positive","ncit:Qualitative","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:c2487b2d-d759-4d01-8887-4677b3b8778d","Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. ","ncit:negative","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Clonazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:c239fd23-a51a-41f4-9cb0-4b1ffd6ce8f3","Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:a9301ad6-1651-48af-b939-c0dcb6ca2e0e","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","fluvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:a0ed82cb-a10f-4f91-a1d8-dd01311247e3","Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).","ncit:positive","ncit:Qualitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:a03a6a53-a4fd-4a65-ad94-a0c95c86d6ba"," In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). ","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FE4929E2-95AF-4B8F-BE49-60494F3973D6","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FE1A477B-EB1A-420B-AD02-C547D6535DE1","There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.","ncit:positive","ncit:Qualitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FCB599A7-C7CF-4E31-AAD2-7226E2C20D8B","Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%. In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:FC60C874-AF84-492D-B58B-A4B2107FF14D","In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:negative","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:FBB37EFD-B8C7-4284-B91F-CEB1D2704EFA","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","furosemide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:FB923729-1203-488D-9A56-696B720C1DD3","Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.","ncit:negative","ncit:quantitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","stavudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:FB77F85C-78C3-42B3-BBE8-77FA8FC73110","Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","tacrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FB06B874-B4FF-4D62-8B98-AF71219A34FD","In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.","ncit:negative","ncit:Qualitative","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FAE98F89-D4F8-4983-B42C-00D341030245","coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.","ncit:positive","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fexofenadine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:FAD38374-2DA6-4E0F-9DAB-8670150EA858","Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.","ncit:negative","ncit:Qualitative","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:F8F82CE1-990E-43E5-ABC7-D01C3B482DE1","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:F89BAE36-DD75-45FA-82C6-01F61A2EF178","Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.","ncit:positive","ncit:Qualitative","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:F7B4BD0E-C259-47A4-91D5-44F985F3DD55","When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.","ncit:positive","ncit:quantitative","LIPITOR","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:F6392081-33E7-4C2A-93A5-6D3807A06F87","An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.","ncit:negative","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","terfenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:F4DEE747-44B2-415E-9E6F-F3F338479E38","The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours.","ncit:positive","ncit:quantitative","aminophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:F4216EDF-FCFF-4E53-A18F-D7FD2EF12605","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:F3EDD32E-0A29-4402-89FA-A89B8957004D","Phenytoin: Nifedipine is metabolized by CYP3A4. Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%. When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary.","ncit:positive","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:F357BBE2-9BF5-4267-9756-8DEB6A3C2098","Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","lopinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:F2DC0496-DA9C-41B6-8A47-26244C1FD0ED","Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.","ncit:negative","ncit:quantitative","fexofenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:EFFC3A3A-039D-4998-9815-95E98044379A","A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone","ncit:positive","ncit:Qualitative","oxycodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EF598A75-7B5F-4B3A-B26D-FBBDC77D375B","The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. ","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EF251D91-3A73-43BC-9A2B-D62E5A26B616","In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.","ncit:positive","ncit:quantitative","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EED1D7DF-CF12-4B75-88EB-142933594019","Diazepam does not alter the pharmacokinetics of propranolol","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EE5F7A88-9E36-4D87-B3C7-B9277EADF053","Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:EE1F97A1-3994-4C03-BE01-602013D7CCD4","Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.","ncit:positive","ncit:Qualitative","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:EDC6CD27-9DCF-4C76-A062-3E96FC9ACF29","Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.","ncit:positive","ncit:Qualitative","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:ED1C29DD-F044-46E9-B0DD-49A4A0780D15","Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.","ncit:negative","ncit:quantitative","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EB32DF82-19F1-4506-BA93-CF38DE05C68A","A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (<5%) in 3 of the 21 subjects after fluconazole treatment.","ncit:positive","ncit:quantitative","norethindrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:EA6F5FF9-30E0-445A-97B4-BD3761D92400","Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.","ncit:positive","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","indinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:EA29D42F-D09D-4FB0-9AA6-3E2877C75092","In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:negative","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","terfenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:EA11E66F-660C-46D5-B222-C541A09953D4","Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%. Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.","ncit:positive","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E9F154A7-885F-4423-BC72-8B64186E3C91","Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E9CDCB47-0AFD-42FA-A005-046710AA7DA9","Conivaptan is a sensitive substrate of CYP3A. The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated. Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively ","ncit:positive","ncit:quantitative","conivaptan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E9A57A64-DDBD-40E0-9021-D8E47C66965B","CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general. Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.","ncit:positive","ncit:Qualitative","Nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E999ED3C-6E10-45C2-B29C-2177D596BC31","Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.","ncit:positive","ncit:quantitative","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E89CD056-93E9-4058-98D3-EE3431868907","Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.","ncit:positive","ncit:Qualitative","magnesium-aluminum hydroxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E8841241-0057-420C-85E3-2C0EC4B7CC39","Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.","ncit:negative","ncit:quantitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","didanosine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E82FCB86-DFB8-480C-8FCE-F76861A7F4F0","Coadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin","ncit:negative","ncit:quantitative","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E79A8B07-C97C-4FF7-AAE4-9F4E086B09E0","Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively","ncit:positive","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","synercid","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E7915644-28A2-47FE-9EE1-B43B53DC64CA","Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.","ncit:positive","ncit:quantitative","atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E78B48BE-9D1F-4F71-93E3-934B0E1BA43D","Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.","ncit:positive","ncit:Qualitative","magnesium trisilicate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nitrofurantoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E751420E-8BEB-48BD-9D49-60039913B2ED","A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).","ncit:positive","ncit:quantitative","glipizide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","miconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E51934A9-2B74-4D8F-9620-082A01E3B7D0","7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium","ncit:negative","ncit:quantitative","ODV","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E43E2315-081D-4703-B4E6-7A9270E74E0C","Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.","ncit:positive","ncit:Qualitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","didanosine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E2B32452-94CE-429F-9E26-4DD8ED692BAA","Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS).","ncit:positive","ncit:Qualitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E29379BB-3B42-46F1-AAD5-9403BAF6750F","In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.","ncit:positive","ncit:Qualitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E1CD71BF-2DFA-4223-9875-A845BE0E2E22","In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.","ncit:negative","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","mexiletine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:E0C7F5D3-3AB4-4981-99E9-08634670F1AF","ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%","ncit:positive","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ranitidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:E055844E-921A-44DC-B47A-D5FDBB96AEA9","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DF8EC3BF-39F1-425D-BB63-1179252277CF","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","antipyrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DF75E64A-4D45-4393-A03E-A3D34A40FC13","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered","ncit:positive","ncit:Qualitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","mesoridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DF593025-C203-4842-93CD-443367C8C8E1","7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%. However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine. ","ncit:negative","ncit:quantitative","ODV","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","Cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:DE560C91-21D6-4968-95FA-224203CA8EF9","There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole","ncit:positive","ncit:Qualitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:DE08B357-9C54-458B-8993-B39DAE0D54A4","Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy)","ncit:positive","ncit:Qualitative","fosamprenavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DD6F75BD-E3E4-4A30-A3AE-9FBC3E0C0C7E","Rosiglitazone: Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.","ncit:negative","ncit:quantitative","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DC689962-E4BB-409E-B033-E5EBA74DB441","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:DAADF25C-A4FE-4326-B9E7-9D0E8C313E5C","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","celecoxib","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DAA11CB5-C5AA-428B-850D-63A524586BA1","Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.","ncit:positive","ncit:quantitative","Colestipol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:DA5D5837-3580-49DF-8E5E-F517AB8DF46C","Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.","ncit:positive","ncit:Qualitative","stavudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:D895BF59-A109-46AB-82C8-77658F9BA940","Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:D730927A-7A5C-4283-B110-CA21BC2EF052","An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant pharmacokinetic interaction between fluconazole and azithromycin.","ncit:negative","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","azithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:D4128694-D50D-4454-B1F8-378B825A9152","Verapamil can increase doxorubicin levels","ncit:positive","ncit:Qualitative","doxorubicin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:D19B9A2C-9CC4-4AE1-BB61-F344D5904F19","Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.","ncit:negative","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","zonisamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CE80E177-0F4A-4A1D-A628-4681706A6E87","Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.","ncit:negative","ncit:quantitative","magnesium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:CE2BC04A-D693-485A-B82C-FEE60FDF69CE","Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].","ncit:negative","ncit:Qualitative","stavudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ribavirin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CE25948D-82C0-4514-B23D-B114BF692D50","Venlafaxine did not inhibit CYP1A2 in vitro. This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.","ncit:negative","ncit:quantitative","caffeine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CD5613AC-945E-4FC7-A565-D7E9BE8DEF19","An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response.","ncit:positive","ncit:Qualitative","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CBF53664-B035-4084-8367-8B462FC0A703","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CB6F6828-0358-4241-8207-69A8687C9B37","Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:CB05608A-6777-47D4-91CD-D7D6CD8FE1DA","A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations","ncit:positive","ncit:Qualitative","oxycodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:CA91E21C-69C9-4FC1-B9F5-8D6F67ED2AB2","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C9ACBCB7-738B-47D3-9E81-7BC584E142D6","The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known.","ncit:negative","ncit:quantitative","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","epoprostenol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C93B2C33-8805-49A5-85A4-1E72F0142400","AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA","ncit:positive","ncit:quantitative","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","glyburide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C913040F-2661-4824-A792-879B37559C2E","Nefazodone plasma concentrations were unaffected by triazolam.","ncit:negative","ncit:quantitative","Nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C799DD5F-A65F-405A-8A34-C4328849306F","Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively","ncit:positive","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ranitidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C76DF617-449A-4AFD-AAB5-D75192FE059C","For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. ","ncit:positive","ncit:quantitative","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C710E7F2-14E9-4D9F-AF4D-BB3BB31DDDE1","Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%","ncit:positive","ncit:quantitative","magnesium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fexofenadine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C6DF6A97-FFFB-4636-9994-C20645D2B05E","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","acetaminophen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C616CA3F-D5BA-4A06-8DEC-31C84D750966","VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.","ncit:positive","ncit:quantitative","vaprisol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C616274C-6434-4062-9046-70A384AFFFEE","Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil.","ncit:positive","ncit:Qualitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C5143776-1B0F-49BD-A1D1-96D30189B10F","Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.","ncit:negative","ncit:quantitative","magnesium hydroxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","sotalol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C4859CB1-5B28-4858-BE98-DFB12A75E0E1","No significant interactions were found between nisoldipine and warfarin or digoxin.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C47F66A7-150E-4483-B9FD-850D9690B309","Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.","ncit:negative","ncit:quantitative","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aluminum hydroxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C44331BB-773C-4338-8049-4956F3685832","Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold. Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently.","ncit:positive","ncit:Qualitative","tacrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C366A547-1D1B-4513-8A36-6C5B95F91B6D","Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.\n\nVenlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively. Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).","ncit:positive","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C2375BD2-98CE-498C-A653-8F353DC2AFC3"," In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole.","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C1A033D4-02A5-4472-83C4-DB543DEF2BCB","7.4 Haloperidol\n\nVenlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC. In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged. The mechanism explaining this finding is unknown.","ncit:positive","ncit:quantitative","Haloperidol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:C19232C5-C67F-4BDB-B93E-0D5C690AD368","Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C16B9331-360B-4263-84B6-78CEF02D1351","Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.","ncit:negative","ncit:quantitative","zonisamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C06A5B4B-1DAF-4DAB-B57F-EC5FAD9EE0E4","In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. ","ncit:positive","ncit:Qualitative","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:C065E6E2-D8D0-471E-9A02-F7F39A2CED51","Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered.","ncit:positive","ncit:quantitative","quinupristin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BFBA5C57-7297-4D17-B1ED-B12C0FFB6D77","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BF5B9586-8B87-4545-B4AB-36CD8A6842A6","In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.","ncit:positive","ncit:quantitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","tacrine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BF1B5DC0-5CFC-459F-A0BE-B1DAAF37A993","Coadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate","ncit:negative","ncit:quantitative","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BDC8060A-B279-4AA2-8368-F3D68E94F4A3","Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. ","ncit:negative","ncit:quantitative","7-hydroxymethotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","naproxen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BD835ACB-0856-411D-851D-4B2286191CC0","When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.","ncit:positive","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BD2B8D6E-EBE4-4F56-9A06-3234FA3AE367","Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.","ncit:positive","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BC8DFC77-19FE-42F8-93A9-FBB9DEE32C41","Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.","ncit:positive","ncit:quantitative","quinidine sulfate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BBE5812F-4BD5-46A9-983B-F7350B4B8065","In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.","ncit:positive","ncit:quantitative","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","bosentan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BB822DA9-9165-43B8-87AA-B14F889A5494","AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.","ncit:negative","ncit:Qualitative","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BB3BDF16-5434-4F07-AD83-70BF147C85F0","7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium","ncit:negative","ncit:quantitative","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BB2610C9-3805-4790-A5E6-5B5E60085C48","Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.","ncit:positive","ncit:quantitative","sucralfate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BB1B918C-FA47-4A3B-A57C-82BE80FC47B3","Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.","ncit:negative","ncit:quantitative","sotalol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aluminum oxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BAF54945-3A8A-4370-873C-E3FB790ED868","Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]","ncit:positive","ncit:Qualitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:BA4FC9A4-D363-4102-A981-9BB361F8EC8C","Doxazosin: Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively. Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered.","ncit:positive","ncit:quantitative","doxazosin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:BA3A3EA6-25DC-4A92-9A1F-0EA2AFBBB333","The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B984DB7F-9CC7-4D0F-B1E5-AAC262C7D72E","Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.","ncit:negative","ncit:quantitative","Felbatol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:B8588523-C329-4303-ADDC-E0587156E5F6","Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%.","ncit:positive","ncit:quantitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","norpropafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B8024119-B326-4A20-9801-460A2876BCEE","cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined","ncit:negative","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B786BEC7-3FAE-4306-BEC6-F3629CCFB24B","Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.","ncit:negative","ncit:quantitative","indinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B647486F-BD6C-4C02-A99B-986CFF74FD11","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","metformin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:B5CA50CB-8AAD-42D1-ADB9-A524369D214B","Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:B5821CB1-C20E-47EB-95E6-9E2CFB1CEF28","Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%","ncit:positive","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B4B3175F-9FA2-44AD-B554-4EB2C2A25A54"," The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","cyclophosphamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B391108E-3A30-4804-9C04-0ADDB5278361","In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.","ncit:negative","ncit:quantitative","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B33CECFD-3CA7-447A-8B97-83947DDADD1B","Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3.","ncit:positive","ncit:Qualitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","isoniazid","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:B1FD31E9-3F5A-4C6F-88AC-0F64B30A5F5F","Verapamil therapy may increase carbamazepine concentrations during combined therapy.","ncit:positive","ncit:Qualitative","Verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:B17DEDF7-5117-4719-B40F-88EDC0752913","ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%","ncit:positive","ncit:quantitative","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","ranitidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:B115457B-6573-489E-97A1-794F562EF7E2","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:AFC6F324-041F-49E5-95F8-8106928974F3","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:AF0446CB-FFA0-4B74-BA32-C4196D47DB19","In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:AB44741D-BFF6-47E0-B101-48CB77C6FFE7","In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir","ncit:positive","ncit:Qualitative","trazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:AA70235E-0C4F-49BA-8DCD-EBA299F33730","No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.","ncit:negative","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","lidocaine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:AA4CD511-5DB6-4C87-B4A7-2867E9097700","Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced ","ncit:positive","ncit:quantitative","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","gemfibrozil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:A8C36DC0-F129-4230-B792-7585A33EE49D","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","ramipril","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A899C9F5-4260-4BFA-B02D-21CC29BE7E52"," Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.","ncit:positive","ncit:quantitative","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:A81CDF4E-B534-40E7-AB46-5DB589762ADB","Verapamil does not affect the pharmacokinetics of propranolol","ncit:negative","ncit:quantitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A80E23B9-D075-4E84-A308-F5F928749CF5","In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.","ncit:positive","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","tolbutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A7A1044A-5798-4AC3-8C4C-D73C3DB57AF5","There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole","ncit:positive","ncit:Qualitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A783503F-D134-4BA3-811E-99FCE28F6D1F","An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response.","ncit:positive","ncit:Qualitative","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","gemfibrozil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:A6E4CE45-BCB0-440E-8EE0-970472A2D684","Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A678B4FF-ED79-4066-874E-3DFADBB43A7D","A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol. ","ncit:positive","ncit:Qualitative","felbamate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","gestodene","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A62379B0-048F-4BBD-908C-20C585F768B6"," The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered.","ncit:positive","ncit:quantitative","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","trazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A5C5E90D-971B-4483-ADB6-6A5090496BC5","Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.\n\nVenlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PM's -2% to 206%), and AUC values for ODV increased by 23% and 33% in EM and PM (range in PM's -38% to 105%) subjects, respectively. Combined AUC's of venlafaxine and ODV increased on average by approximately 23% in EM's and 53% in PM's, (range in PM's 4% to 134%).","ncit:positive","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ODV","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A59461AD-50B9-4CEB-AE18-C0F87F411CF3","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered.","ncit:positive","ncit:Qualitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","thioridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A539A877-AAD7-4856-8215-B23F3D72BCE2","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:A25E616C-DFAE-43E7-9DDF-ACDA2E92B74E","Chronic administration of clozapine with risperidone may decrease the clearance of risperidone","ncit:positive","ncit:Qualitative","clozapine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:A1055A0E-6A6F-4BFE-9EC0-3398CA97CA6F","When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.","ncit:positive","ncit:quantitative","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:A0943D4B-8A8C-4AF8-9379-3CCBBAE9ADEE","Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.","ncit:positive","ncit:quantitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9c146f41-7baa-48be-87cf-9c4bbb86bb14","When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold. ","ncit:positive","ncit:Qualitative","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9b8dff33-ba65-4308-a550-9e23cf13f80d","Desipramine Blood levels of desipramine have increased with concurrent methadone administration.","ncit:positive","ncit:Qualitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9F63A54D-8C54-4231-AAA6-C4047ADAD4D0","In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9F421ABF-E840-4034-A294-5AA203A2965E","Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9ECD2E84-40E0-41BB-9FA4-619131364D1F","Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.","ncit:positive","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9E783620-42AF-4752-A325-B509AFDFFB28","Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration","ncit:positive","ncit:Qualitative","normeperidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9DCC526E-8763-49C5-98FB-B1613386AA3D","Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.","ncit:positive","ncit:quantitative","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9B2C0E07-15F0-43CE-923F-D26DDE71CE6C","Erythromycin:There were no significant interactions between risperidone and erythromycin.","ncit:negative","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9AFEC25A-7770-4D4D-97CA-8F2103A062E7","Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%","ncit:positive","ncit:quantitative","fexofenadine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aluminum","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9AE77895-6C97-4379-AA30-0AB6E0516243","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9A39B986-4679-4FD8-A2EF-330D6AC97D86","An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole. There was no significant pharmacokinetic interaction between fluconazole and azithromycin","ncit:negative","ncit:quantitative","azithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:995B95AC-1B6A-4217-BB36-CB336400C107","Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.","ncit:negative","ncit:quantitative","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:980D8375-2A34-47AE-9648-D44F8E1E5609","The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9804C8C5-3201-4A0F-9FA1-C6E8E1B1E28D","Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.","ncit:positive","ncit:Qualitative","aluminum hydroxide gel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9792023F-D406-440A-A47B-F5324C3B97A2","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","lovastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9755A944-F1F2-455B-8ED1-D419D67919F4","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","valsartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:9738DA95-2559-474C-8348-3FFEE9A726D4","In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.","ncit:negative","ncit:quantitative","mexiletine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:964D229E-7742-4278-8030-45571F6470DC","In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6","ncit:negative","ncit:quantitative","donepezil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:960DF358-FF78-4C37-91FE-21CF19E22817","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:944BC5B8-BDD1-44DB-B241-9F8E3D97E750","A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate.","ncit:negative","ncit:quantitative","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:92066FE5-1405-41B1-85CA-8A8C29A94EB7","Erythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).","ncit:negative","ncit:quantitative","fluvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:9169FF55-28DB-4701-B68A-358850EDFD95","The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers. In the study, subjects ingested placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was orally ingested on the first day, 0.05 mg/kg was administered intravenously on the fourth day, and 7.5 mg orally on the sixth day. Fluconazole reduced the clearance of IV midazolam by 51%. On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively. On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively. The psychomotor effects of midazolam were significantly increased after oral administration of midazolam but not significantly affected following intravenous midazolam.","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:91239536-9595-4DEC-9FCC-6F4DE09C1950","In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6","ncit:negative","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","galantamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8FF24A6F-2178-43B1-A0E1-109514E57181","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8FD8C04A-335E-4FB2-9B0E-FAAC3B79188B","Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.","ncit:negative","ncit:quantitative","indinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ODV","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8E779221-26AC-4792-A908-D233B9FFDD11","No significant interactions were found between nisoldipine and warfarin or digoxin.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8E443B07-E970-437D-AB7C-CAFC67F819EC","In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (14±6% vs. 7±3%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in tacrolimus clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin administration.","ncit:positive","ncit:quantitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","tacrolimus","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8DEE8F1E-7CD4-438F-8F93-BDC31DD6C2DB","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","cyclophosphamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8DD896DF-7FBD-4E79-9415-D948A381C673","The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. ","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","theophylline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8DBA127A-5E66-4CAF-865C-F0D818CFF0DD","In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8D2365AB-E6ED-4F38-8690-7EB2E8B7E934","Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored.","ncit:positive","ncit:Qualitative","penicillins","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","methotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8C7C035E-1863-43C3-9F69-DDB013B30715","Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8B9E1BD5-B077-42D2-81BD-F76692A03855","coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.","ncit:positive","ncit:Qualitative","fexofenadine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8B8E52BE-280D-42B8-A550-ACAFE604C677","Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%).","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8B2D8833-1AE4-41FA-B72A-180709AECC86","Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).","ncit:negative","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","zonisamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:8ABB3BA6-84B3-4075-AAC2-963166B6BD0F","In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%).","ncit:positive","ncit:quantitative","tolbutamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8A5CA598-1189-4528-8FDC-6CBBD28259F2","No significant interactions were found between nisoldipine and warfarin or digoxin.","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:897CCE4F-BAA0-4285-A7DC-C44CECD44CAF","Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone","ncit:positive","ncit:quantitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:88A53C37-C91D-4321-972E-215E698B9BF3","Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol","ncit:negative","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","norverapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:888FCFEC-639B-4FFC-8B14-02460F57BD59","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","ramipril","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:86E643D7-4766-47E2-A6AA-2903937C47A6","In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:85BC7B1F-9961-47FC-9A7E-0A309C19F4CA","Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when FLAGYL (metronidazole) is prescribed for patients on this type of anticoagulant therapy","ncit:positive","ncit:Qualitative","metronidazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:854A5EDE-6356-45B0-BCB9-BE45DA770390","The AUC of propafenone is increased by more than 200% by co-administration of propranolol.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:84BE9570-CE24-477B-B7B9-5F2B30796443","Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.","ncit:positive","ncit:quantitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:846750BF-E8EB-41CE-B49B-398DE3A2CB2C","In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).","ncit:negative","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","cisapride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:83E35C31-8662-4D63-8D75-4E5962696051","Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.","ncit:positive","ncit:Qualitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:839D16FA-BCC2-4042-B5A5-DD0504556C7B","Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)]. Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone. A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold. Avoid concomitant use of propafenone and quinidine.","ncit:positive","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:825E94D7-A56C-4804-AACC-D6EB9189DE40","No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients.","ncit:negative","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lidocaine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:81D18ECD-60AA-44D8-99E7-C390ADFDD89D","A third study evaluated the potential interaction of once weekly dosing of fluconazole 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (<5%) in 3 of the 21 subjects after fluconazole treatment.","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:808D82BB-EA92-41E7-A49E-919E3DC14991","Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes","ncit:negative","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","zonisamide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8089D978-0806-4028-BD81-F0F8C4FFD1CB","Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone","ncit:negative","ncit:quantitative","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","metformin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:8013BBBD-8DEE-46CE-8976-F062172E89E5","Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.","ncit:positive","ncit:quantitative","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atazanavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7F36906C-61F7-47F9-8E11-13A7ED27BAAE","Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.","ncit:positive","ncit:quantitative","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7F34F894-7585-47C8-9ADF-AD1FB473036B","Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations","ncit:positive","ncit:quantitative","cholestyramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7EB942F3-FD6D-45F5-A4A2-896172791DC6","In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.","ncit:negative","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7E5C90B6-BAC1-420E-AD10-42A507CB7C18","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","prednisone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:7E0CFC7F-65D4-4237-A8ED-2B7239AB9784","The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. ","ncit:negative","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:7DEBB504-068E-4D02-8EB4-F9ADA8925EA5","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7B86D6B5-8B50-4756-92C6-5C423800ACBE","Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.","ncit:negative","ncit:quantitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7B19BF0D-C186-4BCB-B3DB-C6682B64E203","Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.","ncit:positive","ncit:Qualitative","amiodarone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7ADA7DCD-681F-4647-9F44-B23D4092E365","In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and Paroxetine Hydrochloride Controlled-Release Tablets is contraindicated (see CONTRAINDICATIONS).","ncit:positive","ncit:quantitative","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:7938EE79-51DD-48D3-B15C-327279D06D9D","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","amlodipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:79220EEF-2BE8-475D-B34F-ADE926804A49","Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.","ncit:negative","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7873E960-693B-4DEE-BD94-C1267A039FE6","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:7539222E-C7EA-454A-A9E1-00EE29B32AA7","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","pravastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:742DE683-4894-4071-A2F6-3504C182477A","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","celecoxib","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:740fe145-9da4-4a96-b938-b78b50238838","When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. ","ncit:positive","ncit:Qualitative","triazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:739C1B5D-D0CB-4D38-9249-6A1444BE810F","In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:737C9A37-EE50-4C96-83FF-561BF3B1EE33","In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.","ncit:negative","ncit:quantitative","simvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:71E8A105-B07C-4899-AF5A-BD798C3C484A","Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.","ncit:negative","ncit:quantitative","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:70D2BD99-142A-4CA1-8633-4E3F86EA93B1","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","vindesine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:70244266-E3FE-485B-8B58-CAA51304F7C2","Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively","ncit:positive","ncit:quantitative","furosemide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:6DF383E4-F15A-49B5-8192-02F522393878","In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.","ncit:negative","ncit:Qualitative","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6DB470AF-7CE8-4FF2-BD76-B7A5614F1FE1","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","prednisone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:6DB09AB9-41FE-4ED0-AFBF-06B5CE5F497A","7.5 Lithium\n\nThe steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected. Venlafaxine had no effect on the pharmacokinetics of lithium","ncit:negative","ncit:quantitative","Lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6B30932B-00C6-46E8-8CDE-7D8631A0CB5B","Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine. Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine. In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine. The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02. The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects. Hypertensive subjects receiving 10 mg q.d. nifedipine alone or in combination with cimetidine 1000 mg q.d. also experienced relevant changes in blood pressure when cimetidine was added to nifedipine. The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6ADA22D4-36CE-4212-8A7D-8F44DE2131D9","There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole","ncit:positive","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6AD597BA-B67F-436B-BDC1-D4B581200E5A","Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. ","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:68a94026-5f3a-4303-a4cb-b352e198d477","CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A.","ncit:positive","ncit:quantitative","atomoxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:68ECE5EE-A978-45A8-9A38-A4EACE88CBDA","In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.","ncit:positive","ncit:Qualitative","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","revatio","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:68D24B02-387E-40C6-B7C6-F02189114494","Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","levonorgestrel","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6881E425-4339-4018-BEDA-1111C2CBC350"," Propranolol did not have an effect on the pharmacokinetics of fluvastatin.","ncit:negative","ncit:quantitative","fluvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:687CEA0C-BDE9-4E88-AD0B-7ACD0FC9F9DF","In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:6837ACE2-A818-4E80-A60B-2CF9D844E368","7.2 Cimetidine\n\nConcomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%.","ncit:positive","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:677DCD4D-7FD4-4EE7-AF77-0C09D142FF98","Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.","ncit:positive","ncit:Qualitative","diltiazem","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:67698A7A-697F-4F21-8B88-594BC2F9C15C","Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. ","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","7-hydroxymethotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:66AB777F-E2DB-4B34-B616-11FD8AB37336","Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.","ncit:positive","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Felbatol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:65c7a5ee-55a7-491e-94c1-743005fa5753","Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions ).","ncit:positive","ncit:Qualitative","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:65954627-72FD-4BBB-BE0B-A37010B28825","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:65673BB3-448F-40F8-B0E6-2290B4E7670C","In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.","ncit:positive","ncit:quantitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:65599449-4C95-49A1-8878-6B26A30B94DE","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","azithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:64651AE6-EC9E-4F00-AE67-403B39AE8E2A","Coadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","amlodipine besylate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:64405421-2608-4CFF-B9B7-24BEF8D08CD1","AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.","ncit:negative","ncit:Qualitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:635A8912-2E77-4AD2-81FB-45E1C9894AD9","Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].","ncit:negative","ncit:Qualitative","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ribavirin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:62E23A1D-C9E8-4679-BC1E-882277CB88AC","Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:61C3F83D-35C4-4073-8027-13127C4B0AAA","Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects","ncit:negative","ncit:quantitative","glimepiride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:60E6EF68-9B3F-4F29-A307-34BF23344F95","The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol. ","ncit:negative","ncit:quantitative","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5f590522-55b5-40cd-9c5e-af807cac7d26","Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. ","ncit:negative","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","bisoprolol fumarate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5d095f5f-04bb-46ea-8406-4849b3b0ab6a","Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. ","ncit:negative","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Clonazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5FF7629F-F304-4A86-BE42-01786FB50EDA","Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.","ncit:negative","ncit:quantitative","fexofenadine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5F9E8D23-F285-4C66-8DF7-7C419412D9C9","Diltiazem: Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively. Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered.","ncit:positive","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","diltiazem","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5E480179-EDB1-4A8E-ACC2-B79CCF6CEAA5","Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).","ncit:positive","ncit:Qualitative","nelfinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","azithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5DB2C00F-068E-47A6-99B8-ABCF24FE244A","Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin.","ncit:positive","ncit:quantitative","clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5D918B1F-3225-4686-A401-07868FC465A5","Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours.","ncit:positive","ncit:quantitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5CFBDE38-D860-4635-969D-A12C4F1C35DB","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","indomethacin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5CD02AB9-D8E7-4975-A504-60D22F803647","Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.","ncit:negative","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","α-hydroxymetoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5CB32F75-2A27-4367-A67C-24BB689F153E","The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.","ncit:negative","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5C29FA5D-F702-4527-A871-43B8D82BC8AE","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5C0759EF-E008-4093-B19D-5A077456D59D","In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir","ncit:positive","ncit:Qualitative","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","trazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5BFAB712-E552-497E-A61F-9D79D928F612","Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively","ncit:positive","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","conivaptan hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5B9FB22F-2A9F-4FFD-904A-0B5E6B0EC961","In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.","ncit:negative","ncit:quantitative","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5B0BA3D0-BE5E-4C18-9751-42A24A039F70","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5AA09661-ECCC-4894-BF63-91E666CC8BAF","Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren","ncit:positive","ncit:quantitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5A0DE6C2-68AC-4515-8616-46FB047F6410","Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","mesoridazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:58BF3512-922E-41A4-AFD3-021EAD6B68E2","There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole","ncit:positive","ncit:Qualitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:587EE8E5-5403-4BAD-B8F7-CA5138BEE439","Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren","ncit:positive","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:586b64ec-1adf-427a-a8bd-ab5ecb90e88c","Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. ","ncit:positive","ncit:Qualitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","bisoprolol fumarate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:57955037-e035-4019-ae0a-285f09ecca32","A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily. ","ncit:positive","ncit:quantitative","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5771D074-1193-4EB7-997B-31710E663873","In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. ","ncit:positive","ncit:quantitative","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:57505AB0-C496-4EE9-96B3-7C5E98ADC57F","Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH","ncit:negative","ncit:quantitative","ranitidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","rosiglitazone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:56F78626-4EE9-4038-ADA8-61D7D5DDE571","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ketoconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:56D61D81-2CD2-4647-BAED-D5DA6D85FC1B","Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.","ncit:positive","ncit:quantitative","sotalol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aluminum oxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:558c8e83-e92a-4029-a977-c378c0537b44","Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ","ncit:positive","ncit:Qualitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5552e8f8-22f2-49d3-8640-85c2696bdc1a","7.2 Effect of CYP2D6 Inhibitors on Atomoxetine In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). ","ncit:positive","ncit:Qualitative","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:54B4A89E-81BD-4967-A392-EEDDFFF731BA","Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.","ncit:positive","ncit:Qualitative","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","clomipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:541EE0BD-455D-4A7A-854B-562676BFC39B","Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone","ncit:negative","ncit:quantitative","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","metformin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:5372C985-BD8B-48DC-919B-78E26F288022","In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.","ncit:positive","ncit:quantitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:52ECA2D2-D21E-43F3-9420-1ED17F20B44E","Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.","ncit:negative","ncit:quantitative","O-desmethylvenlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:52EA728D-4B57-4D63-9BBC-0060571DD8C0","cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined","ncit:negative","ncit:quantitative","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:5299D5E7-53AE-4520-AE5A-6280B3954B0A","In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir","ncit:positive","ncit:Qualitative","indinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","trazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:526BAAB1-665D-4561-946F-0E42B851A7BA","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","amlodipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:517fd3ad-33c7-46d1-825e-4e8b17f57016"," The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.","ncit:positive","ncit:quantitative","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:51450C97-6C41-4FBD-8342-15BE45A2DDE8","In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol.","ncit:positive","ncit:quantitative","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:512D3C59-8107-469D-B0FE-88AA316A2B12","Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined","ncit:negative","ncit:quantitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:502B7512-035A-4DD5-8452-73F76F70C976","Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine. However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.","ncit:negative","ncit:quantitative","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4e6206f8-db1f-4feb-9027-c6e1a29d7488","These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  ","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:4db0f8de-9ead-482c-a94b-5d7156270825","Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. ","ncit:positive","ncit:Qualitative","atomoxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4FEB7EE4-B778-488B-B553-BA81C21A1546","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4E7064BA-7C36-498D-8ADE-66041B589D66","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","ibuprofen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:4D6663BD-2805-46B5-BCAF-8863DFD12AEB","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4D356DAB-552D-4B0B-8D1A-FA3063EB5C91","Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.","ncit:positive","ncit:quantitative","felbamate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:4D30D711-0840-4F57-9D39-685BB0CE7916","In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.","ncit:positive","ncit:Qualitative","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4CBC8554-5F6F-4DB5-82A4-30C03AA012CD","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4BC34D35-17F6-49DA-A8BA-DBBFD0BD7819","In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.","ncit:positive","ncit:quantitative","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","bosentan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4B936CBF-4785-47BF-98E9-C7A58EEE0D15","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:4B03F850-0F84-438D-85C6-2980A81685A7","Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.","ncit:negative","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:4AF8E204-1E57-411D-9013-3CA029E06DB7","Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","sildenafil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:49f93141-e307-4fb7-80b6-3072848c5675"," The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.","ncit:positive","ncit:quantitative","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:49e2d9d5-7dff-4af5-a191-3572016cd723"," Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%). ","ncit:negative","ncit:quantitative","Ranitidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:49BB1687-760C-4132-803F-8929B3CEA2D8","Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.","ncit:negative","ncit:Qualitative","diltiazem","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:48C60AD1-7D0E-4319-B591-6954F0F27DD8","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lovastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:489AEDFE-F9B4-46D2-A1D5-CE787D9B9F27","The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean ± SD increase in AUC of 44% ± 29% (range: -13 to 115%) and Cmax increased 19% ± 19% (range: -23 to 62%). Five subjects required oral glucose following the ingestion of glyburide after 7 days of fluconazole administration. ","ncit:positive","ncit:quantitative","glyburide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:46EEA3DF-44B0-4E3B-ADA8-171D3C54C7CB","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","oncovin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:46A53F25-C7A3-4D90-8A60-29F0AF4E0BB9","Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers","ncit:negative","ncit:quantitative","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:468ed9c4-680e-43d2-9069-0c9655c0f7e2","In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG. ","ncit:positive","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:4686F1AD-914D-4B59-BE7E-7E0D7F9C6657","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","valsartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:464BFA2C-135D-42E7-BAF8-E1621BE503F2","Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13)","ncit:negative","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lithium","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:44BB6BE7-3CBE-46F0-A9CE-78A2410CDC48","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:42D57CE0-52FA-4011-A83A-18B9E1EFBA36","Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations. In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL. The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL. In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.\n\nIn a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.","ncit:positive","ncit:quantitative","Felbatol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:41EC1F70-B919-4563-BA6C-23B2DE0ACFF8","Erythromycin:There were no significant interactions between risperidone and erythromycin","ncit:negative","ncit:quantitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:419C7F38-E49C-4AA8-98BE-BD8D59B65810","Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined","ncit:negative","ncit:quantitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:40D7C070-F1A5-4DA0-A500-0A309BCF13C4","The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. Adjust the warfarin dose as needed by monitoring INR (international normalized ratio)","ncit:positive","ncit:quantitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:40520150-B72F-4AAE-822F-F3A56B8EC9EB","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:404e0caf-107d-41df-8612-00705a164560","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","dapsone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:404894df-3161-4d82-9a9d-01c9eb905271","Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%.","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:3db26fc1-8245-4e6c-8754-f091fc0d21ad","Nefazodone plasma concentrations were unaffected by alprazolam.","ncit:negative","ncit:quantitative","Nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3E6745A7-B0C1-4699-9D1E-BA8D3C68E50F","Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.","ncit:positive","ncit:quantitative","magnesium hydroxide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sotalol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3DF89F0E-9034-4F98-8115-7E7B95EAFF52","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","acetaminophen","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3BBD861C-1870-4BF0-A028-32900CCF9ACB","When a single oral 30-mg dose of immediate-release paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.","ncit:positive","ncit:quantitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3A678043-ADA2-4E23-A2ED-84615B586C07","Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered","ncit:positive","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","dalfopristin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3916A1F8-D023-4A40-8707-E00BD0D82213","Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","saquinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:38D25A1F-8E25-4571-9547-3CA72D3D56A7","Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.","ncit:positive","ncit:quantitative","chlorpromazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:38AC0CC2-CBFE-4584-BECA-B6B209315980","Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil.","ncit:positive","ncit:Qualitative","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:38AB2F50-C6F7-4124-9B32-91648C0230E7","A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.","ncit:negative","ncit:quantitative","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","felbamate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3882CA75-CE54-434A-A979-A8EA8B839507","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","cisplatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:38799FF6-0417-4715-B785-1FDFC7AC26D3","In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide.","ncit:positive","ncit:quantitative","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:38540246-6751-4015-9E87-3728628E0088","A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.","ncit:negative","ncit:quantitative","lithium carbonate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","paroxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:37407B56-9D8F-4BDE-B066-EA324EB422E3","Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil.","ncit:positive","ncit:Qualitative","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:36970922-D30F-4642-BD62-64C6588D1837","CYP2D6 Substrate (e.g., Desipramine) — Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6.","ncit:negative","ncit:quantitative","atomoxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","desipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:36330B96-6498-4A69-94F9-98F5F003CC11","SEPTRA may inhibit the hepatic metabolism of phenytoin. SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.","ncit:positive","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","septra","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:34FDDBBE-BD41-473A-8408-C192CF16217C","Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. ","ncit:negative","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Methotrexate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:3407A3F0-5CF5-40EC-AD36-0C1F5658770B","Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.","ncit:positive","ncit:quantitative","gzdv","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:33F47466-2571-42C4-A381-03919A7C6041","Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.","ncit:positive","ncit:Qualitative","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:327BB2AE-CC56-4759-9D3F-CDAD46111F6C","Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:323C2D54-30AC-4061-B1F7-982FD6756ED9","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","oncovin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3226F016-DEDF-4502-B20A-0E915D531222","Valproate: Felbatol® causes an increase in steady-state valproate concentrations. In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL. The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively. This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®. ","ncit:positive","ncit:quantitative","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Felbatol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:30DEA636-C582-4E10-A80E-0289B40A55B1","Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. ","ncit:positive","ncit:Qualitative","LIPITOR","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","norethindrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:300DD7CD-A3C1-4361-97C1-0AB87357CF9A","In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.","ncit:positive","ncit:Qualitative","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:300743C8-456A-41DE-857C-23574FF88275","Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.","ncit:negative","ncit:quantitative","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:3000DBE6-6334-4BBC-95DC-022FCCB1654E","In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.","ncit:negative","ncit:quantitative","mexiletine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2FE5EEA6-B1FA-40D6-809D-4C00F88DD769","Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively.","ncit:positive","ncit:quantitative","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2F8F8701-9A89-4908-AABF-3F6A6B0C3084","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","metformin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2E2A04B6-D35B-4539-A6D7-FDA17AD8C196","Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.","ncit:positive","ncit:quantitative","trazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2DFDB244-A925-4EFA-9AEE-429B4419A69F","Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.","ncit:negative","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","bisoprolol fumarate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2DF039B8-30E1-42E4-AF28-CCC8E4381805","Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.","ncit:negative","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ODV","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2DDDB7D1-BB3F-4513-9FC3-61003F59B4E8","The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater","ncit:positive","ncit:quantitative","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","14-hydroxy-clarithromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2DCF9FE4-BE8B-425A-819D-8A6C81975525","Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.","ncit:positive","ncit:quantitative","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","sucralfate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2C899ABB-BA3D-4B6D-A232-E2DC49EE1B42","Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively","ncit:positive","ncit:quantitative","synercid","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2C5B03FA-0E47-4CF7-9ABA-551463D3CB8C","Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.","ncit:positive","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2C3A97D1-9AF2-4269-9AB4-5DB8A97D638A","Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.","ncit:positive","ncit:Qualitative","amitriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2BEDC22E-2EA8-4C42-8B37-9D4196625558","Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].","ncit:negative","ncit:Qualitative","lamivudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ribavirin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2B6220CC-057A-44B0-856A-829A9EE325F9","The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered","ncit:positive","ncit:Qualitative","fluvoxamine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","sulforidazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2B28BF73-0F68-4B78-8463-1B7C442CDAD9","Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","lovastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2B111787-49A0-4BFC-A3FC-417FA10AEC21","Verapamil therapy may increase serum levels of cyclosporine.","ncit:positive","ncit:Qualitative","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2A953CC4-23F6-4525-849F-0A5A2C32E759","Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2A40295A-06C7-4D99-9873-CD21866FED44","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2A1DA9D2-A593-4EF4-BD8F-3CDBCF4819A5","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:29FCBA5D-B9E2-4B61-A0D1-201E0003999F","Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.","ncit:positive","ncit:Qualitative","meperidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:29EDDEA5-0228-4266-9C1C-8E6123745C37","Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. ","ncit:positive","ncit:Qualitative","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","cyclosporine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:29209BF9-47AA-4049-95C1-471E87AFAFA8","Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine.","ncit:negative","ncit:quantitative","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:291AEF6C-E52A-4221-8978-0A988B239E87","A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.","ncit:negative","ncit:quantitative","paroxetine hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lithium carbonate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2818899E-8D71-4CC1-8C44-C22F75638E6A","VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively. The corresponding prothrombin time and international normalized ratio values were unchanged.","ncit:positive","ncit:quantitative","vaprisol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:28097A59-06C4-4372-B5DF-E273C388432C","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","ramipril","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:268F088F-6652-4DC8-BE01-1C667AE682BC","Doxazosin: Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively. Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered.","ncit:positive","ncit:quantitative","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","doxazosin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:246FED77-69AE-4605-9175-2C196767388D","The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.","ncit:negative","ncit:quantitative","conivaptan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","captopril","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:23A29CC0-6840-420A-B08D-9F7E6937F594","Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.","ncit:positive","ncit:quantitative","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Cholestyramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:2213C13F-62D0-4841-9120-A68FB8089549","Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","lansoprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:21F405B7-4F22-4193-BD1F-3752F9723002"," Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.","ncit:negative","ncit:quantitative","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:21DE8793-4F0E-4DE8-AB49-FB83D02C8C3A","AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.","ncit:negative","ncit:Qualitative","norethindrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:218DB8AC-C8DC-4A8A-A3F8-1B391C612451","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:218D4E79-F72A-41CA-B54F-F8DB66F996C1","Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.","ncit:negative","ncit:quantitative","lorazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:2170C968-DE55-497F-9E90-B298C10C35F0","The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.","ncit:positive","ncit:Qualitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:21628032-8AFE-4ED6-86E0-4D6E480B1DC0","Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).","ncit:positive","ncit:quantitative","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:215FC1CD-1462-4FD2-8E08-50CC0D281DE1","Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:20F2D3B8-1AF0-434F-8139-53E035F90C2A","The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.","ncit:negative","ncit:quantitative","furosemide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","conivaptan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1d1ec785-9a2d-4f94-91f7-b2fd4938a609","Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. ","ncit:negative","ncit:quantitative","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1c25d34f-1b19-4d01-a8bc-a5272c3c5d05"," A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively. ","ncit:positive","ncit:quantitative","oxycodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1b2f0458-8512-4ff7-9cf0-a11c36cc7cc5","A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively. CYP3A4 Inducers A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively. ","ncit:positive","ncit:Qualitative","oxycodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","voriconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1abd3079-d948-41f4-9aae-e8301f8c94aa","7.6 Oral Contraceptives Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. ","ncit:positive","ncit:Qualitative","ethinyl estradiol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","norethindrone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1D6456DE-2785-4888-87AC-4EFB4B133035","Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.","ncit:positive","ncit:quantitative","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1D5A6D41-E5BF-4905-9702-7DA17F74482A","Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.","ncit:negative","ncit:quantitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","fluvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1D0A9A36-1469-43DB-927C-3422E01D71EA","Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.","ncit:positive","ncit:Qualitative","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","amiodarone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1B87C9E2-9E71-4543-BA4E-B2A78FEE82C5","Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.","ncit:positive","ncit:quantitative","nelfinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","omeprazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1B2EDCBA-D49E-4D92-AD22-AC6C3A6FADDC","The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.","ncit:negative","ncit:quantitative","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","irbesartan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1B21A763-D53B-4881-9A7F-DC1C4B3F8425","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","nortriptyline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1B145A34-470A-4CFA-97E7-2D53B9372910","Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration","ncit:positive","ncit:Qualitative","meperidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","acyclovir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1AF99506-1A57-49A5-8989-799DB345F8AE","Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.","ncit:negative","ncit:Qualitative","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","atenolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1ADD4C68-4EF4-4E45-953D-1EE552C70A7D","Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine","ncit:positive","ncit:quantitative","amlodipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","conivaptan","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1AB37877-FF60-406C-B294-16B8DA972E2F","Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.","ncit:negative","ncit:quantitative","itraconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:19EFE6A5-C977-4046-8526-E3FD7EC60A9E","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","procarbazine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:19759B42-A673-4877-B3AF-CDBC44302F63","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","9-hydroxyrisperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:19352391-8DA9-4DF4-98FC-6FFC230BD255","Phenytoin: Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.","ncit:negative","ncit:Qualitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:18b1b51d-bdcd-4e5c-a65a-f60ea822d315","Coadministration of nefazodone increased alprazolam concentration two-fold.","ncit:positive","ncit:Qualitative","alprazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nefazodone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:18BC6B83-DB23-457C-B70A-397945920538","Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:17F3229F-2BA9-4AE7-B237-9AB727D1BF84","Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.","ncit:negative","ncit:quantitative","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","digoxin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:16F384F2-6BA5-4604-ADEC-3707AB4DACDF","Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration","ncit:positive","ncit:Qualitative","normeperidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","acyclovir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:15A2900B-9AAF-45A2-A032-E281FA828CB4","The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean ± SD increase in AUC of 49% ± 13% (range: 27 to 73%) and an increase in Cmax of 19% ± 23% (range: -11 to 79%)","ncit:positive","ncit:quantitative","glipizide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:158bfff7-49fd-43c1-bc46-561e5f2476bc","These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  ","ncit:positive","ncit:Qualitative","atomoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:13AAE387-F0FD-453B-9D2B-F637D8300274","This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers.","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:137ED6B6-D58E-4B3D-919B-4BF77268CD53","co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone","ncit:positive","ncit:Qualitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:1333B105-7860-4A00-A52D-8FC3D4F835B0","Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.","ncit:negative","ncit:quantitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:12FB1942-6F56-4B0D-9EBA-8077462F8846","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:12B9814C-16A8-457C-BBCA-B47E3F236F82","The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.","ncit:positive","ncit:Qualitative","adriamycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:12534F44-8FD4-4F21-9E61-2A4EA1AF6718","Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.","ncit:positive","ncit:Qualitative","diazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1209694E-3FDB-4A08-A579-76605D36B1D7","Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations","ncit:positive","ncit:quantitative","colestipol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:11d98eae-2004-4abf-9820-461e87cf28fa","Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. ","ncit:negative","ncit:quantitative","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","Clonazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:1124F601-1EE9-4CB1-90E5-4F3DE8208B47","In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. ","ncit:negative","ncit:quantitative","pimozide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:10FC2AE6-3D78-49F7-A50F-BE9A59A3CDC0","Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.","ncit:positive","ncit:quantitative","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","pravastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0bd8b78c-9b5a-4ede-98b4-eb2e0335e9c7","Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin. REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). ","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","erythromycin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0FC9A1FC-0D72-4871-82DC-81A8C658E5A8","Orlistat may limit the fraction of propafenone available for absorption. In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.","ncit:positive","ncit:Qualitative","orlistat","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0F98760D-1183-41B4-9BFC-7410F6D25503"," The exposure to quinidine was not importantly changed in the presence of nifedipine.","ncit:negative","ncit:quantitative","quinidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nifedipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0F84FE85-2982-46F2-AFE6-076708E541B0","Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine. The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h). Imipramine did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of elevated 2-OH-desipramine levels is unknown.","ncit:negative","ncit:quantitative","2-OH-imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0F14E241-486F-4C71-B402-4B8875FC3ED0","Phenytoin: Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.","ncit:positive","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","zidovudine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0D32D3F6-A246-4000-8C48-3C56C98A3892","Therapy with rifampin may markedly reduce oral verapamil bioavailability.","ncit:positive","ncit:Qualitative","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0D0469EB-2B5A-42E4-9C74-B46E5146D6DA","Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.","ncit:negative","ncit:quantitative","desmethyldiazepam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","venlafaxine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0CFD7E69-9F40-4910-8BF8-37AFA7004208","VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.","ncit:positive","ncit:Qualitative","midazolam","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","vaprisol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0CE9A1DF-8DE2-490C-BDED-1F28F4629E27","Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21). However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone","ncit:positive","ncit:quantitative","valproate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0BB35202-8DFA-4B2E-A72C-E1C0C685AD3E","Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin.","ncit:positive","ncit:quantitative","phenytoin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluconazole","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0B83C041-B6AE-460A-BD05-BFF553956708","Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy. ","ncit:positive","ncit:quantitative","Felbatol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction","carbamazepine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:09626BDA-BFD6-4C1C-9BAE-8242F7D7B7BF","Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].","ncit:positive","ncit:Qualitative","tenofovir disoproxil fumarate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","didanosine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:09273082-FAFE-46DD-94E1-FD5060C652BD","Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].","ncit:positive","ncit:Qualitative","ritonavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Atorvastatin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:08D9C061-174E-46EF-AF78-C90119DC56DF","Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA","ncit:negative","ncit:quantitative","acarbose","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","avandia","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0830A501-4DB1-4340-9883-9941C11215DA","Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity.","ncit:positive","ncit:Qualitative","metoprolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","citalopram","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:080F84D7-19CF-4696-9855-AA90426B5537","Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.","ncit:negative","ncit:quantitative","hydrochlorothiazide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","aliskiren","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:075CABAE-EFC4-46A0-A8CF-B1E0377FD016","However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus. Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL. Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly","ncit:positive","ncit:Qualitative","tacrolimus","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nelfinavir","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:069C7626-90BE-440F-93BC-0F96310BC10E","No significant interactions were found between nisoldipine and warfarin or digoxin.","ncit:negative","ncit:quantitative","warfarin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","nisoldipine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:064b871d-11d6-4ea6-b332-4272f2aa3b2f","In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group. ","ncit:positive","ncit:quantitative","cimetidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","sertraline","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0505C3FD-D949-47BA-8DA3-BF23A9FEA75A","Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics.","ncit:negative","ncit:quantitative","metoclopramide","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propranolol","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:04CD5AFF-A9E0-42FF-B3F8-82385101DD14","Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.","ncit:positive","ncit:Qualitative","risperidone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluoxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0313DB5F-EB99-4442-991D-8B993A0F2EE3","Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%.","ncit:positive","ncit:quantitative","rifampin","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","propafenone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:02408539-8675-4E80-A9C6-898FC64BD051","Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See Clinical Pharmacology, Tables 16 and 17 (12.3).]","ncit:negative","ncit:quantitative","REYATAZ","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product","dikbD2R:precipitant-drug-of-interaction","methadone","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:021B299C-1EEC-4750-9302-A14AFE2DAC1B","Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.","ncit:positive","ncit:Qualitative","imipramine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","fluvoxamine maleate","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:021406DC-E1FD-49F5-A46F-2FE7476EE835","Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with Paroxetine Hydrochloride Controlled-Release Tablets is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.","ncit:positive","ncit:quantitative","phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","Paroxetine Hydrochloride","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
"urn:domeoclient:uuid:0134AD2A-C253-4CDE-AF90-97772789E401","Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.","ncit:positive","ncit:quantitative","procyclidine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction","paroxetine","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction"
"urn:domeoclient:uuid:0022A8EE-E25F-4B56-8118-7C7254E293AA","Phenobarbital therapy may increase verapamil clearance.","ncit:positive","ncit:Qualitative","Phenobarbital","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:precipitant-drug-of-interaction","verapamil","http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient","dikbD2R:object-drug-of-interaction"
